In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule

Targeted Molecular Imaging of [68Ga]- Labelling Anti-IGF-1R Affibody Molecule in IGF-1R Overexpression Cancer Patients （Such as Colon Cancer、NSCLC and Gliomas）and Healthy Volunteers

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02916394

Enrollment

100

Registered

2016-09-27

Start date

2018-09-01

Completion date

2020-12-31

Last updated

2020-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Molecular Imaging

Brief summary

The investigators developed \[68Ga\]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.

Detailed description

The goals of investigators are to evaluate the use of \[68Ga\]-labelling Anti-IGF-1R Affibody Molecule as a novel PET/CT radiotracer to monitor IGF-1R expression status. The investigators want to evaluate the use of \[68Ga\]-labelling Anti-IGF-1R Affibody Molecule in IGF-1R expression cancer imaging in adult cancer patients （colon cancer 、NSCLC、gliomas cancer patients）with different IGF-1R expression status.

Interventions

RADIATION68Ga-NODAGA-ZIGF-1R:4：40

No Intervention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Colon cancer, NSCLC and gliomas patients with pathological and gene detection results and did not receive any treatment 2. More than 18 years old 3. A life expectancy of at least 12 weeks 4. Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT) 5. Written informed consent

Exclusion criteria

1. Could not get pathological and gene detection results 2. Pregnancy 3. do not want to write informed consent。

Design outcomes

Primary

Measure	Time frame	Description
tumor SUV value of 68Ga-NODAGA-ZIGF-1R:4:40 PET/CT Imaging	after scanning(at time of imaging)	To quantify the accumulation, a volume of interest using a 3D sphere, was placed over the tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal tissues as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest.

Countries

China

Contacts

Primary ContactYingying Sun

505679386@qq.com18846797135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026